SUPN · Supernus Pharmaceuticals Inc
AI read · Good for SUPN
The AI's read
Supernus is merging with Indivior to build a scaled CNS drug company. Management is pitching $125 million in year-one cost synergies and an 11-drug portfolio. Pro forma shows about $2.2 billion in revenue, $888 million adjusted EBITDA, and net leverage of 1x, which points to solid cash flow and flexibility. The stock is only up roughly 2.4% so today's move looks measured, not euphoric. We'd lean bullish because the deal creates scale, margin upside, and low leverage if integration goes to plan. The main risks are integration execution and any regulatory or commercial setbacks that shave the synergy math.